開催日: 2026年9月21日 (月曜日)
開催時間: 9:00 AM – 4:30 PM
開催場所: Cambridge Innovation Center (CIC), 1 Broadway, 5th Floor, Havana Room | Cambridge, MA
Prepare your strategy. Strengthen your story. Maximize your impact at RESI 2026 & JPM Healthcare 2027.
As you prepare for RESI 2026 & JPM 2027, the question isn’t just who you’ll meet, it’s whether your data, your strategy, and your story will stand up to investor scrutiny.
Certara’s Biotech Forum is a strategic workshop designed for biotech executives, founders, and investors who want to sharpen their development plan, de-risk their program, and enter RESI & JPM 2027 meetings with clarity and confidence. This forum is held in partnership with Life Science Nation (LSN), the organizers of RESI, giving you a direct line into how investors at RESI actually evaluate opportunities, straight from the source.
In a single focused day, we’ll address the early-stage decisions that most often derail promising programs and show you how to avoid them before you step into critical partnering and investor conversations, including a dedicated session on how to prepare for, run, and follow up on your RESI and JPM meetings themselves.
Submit your request to register
アジェンダ
What it takes to walk into RESI & JPM with a program that holds up to investor scrutiny, from science to story.
Learn what investors really look for in a pitch: a well-defined medical need, genuine differentiation, and the regulatory and commercial foresight to back it up.
Get a clear-eyed view of today’s regulatory landscape and how to build a realistic path from IND to first-in-human that also satisfies investors and partners.
Understand what “investor-ready” evidence looks like, from translational relevance to study design to manufacturability and how it translates into value-driving milestones.
Secure your spot for one-on-one sessions with Certara experts and connect with peers over lunch.
Moderated panel featuring LSN’s perspective, as organizers of RESI on the factor’s investors weigh beyond the science.
A forward-looking conversation on how recent regulatory shifts are changing the way companies need to think and plan earlier in development, with a look at where the real opportunities are right now.
The practical, tactical piece – how to prepare before the conference, run productive meetings during it, and convert conversations into real momentum after it ends.
Hear from biotech leaders, investors, pharma, and Certara experts on how early strategic decisions shape risk, speed, and fundability.
Recap key insights and learn how to continue the conversation with Certara’s experts.
Join interactive breakout tables with Certara and LSN experts covering every theme from the day – from regulatory strategy to RESI/JPM prep – to explore solutions for your specific challenges
Fran Brown, PhD
Senior Vice President, Global Head, Drug Development Scienceグローバル医薬品開発における創薬早期から承認申請、市販後に至るフェーズの中で戦略策定とオペレーションに25年以上従事した経験を有します。戦略的な創薬および開発計画の幅広い知見を有し、開発戦略やモデルを活かした医薬品開発の活用に特に重点的に取り組んでいます。
Maximilian Vargas, PhD, MBA
Vice President, Evidence & Access StrategyMaxは、科学的なバックグラウンドとヘルスケア製品開発における実務経験の両方を兼ね備えており、開発中および上市済み製品におけるエビデンスに基づくバリュー＆アクセス戦略の構築において重要な役割を果たします。Leading a team of analysts and focusing on projects involving late stage, launch, and due diligence efforts, Max’ experience cuts across all major therapeutic areas and care settings with special emphasis on CV / metabolic, oncology, gene therapies, ophthalmology, GI, and dermatology. Max and team have designed successful pricing and contracting strategies for products at launch and throughout the life cycle. He also leads projects focusing on managed markets communications strategies.
CEO & Founder, SynaptImmune Therapeutics
Tony is CEO /Founder Synaptimmune Therapeutics, Developing the next generation “Conditionally active and Costimulatory T cell engagers (TCE)” for Autoimmune and Solid tumor indications. He is also the Co-Founder of NextPoint therapeutics, an MPM capital-funded novel IO checkpoint inhibitor, TCE and ADC clinical stage company. Previously Senior Vice President and Head of R&D at Cytovia Therapeutics and held senior management positions at PTC, Alexion, Regeneron, Biogen, Dyax and Ares-Serono developing immunotherapys for autoimmunity and cancer. He is an immunologist with 20+ years of research and development experience developing multiple immunotherapies for autoimmune/inflammatory diseases and cancer including 3 BLAs (TysabriTM, KevzaraTM, DupixentTM ) and multiple INDs.
Submit your request to register
関連コンテンツ
ヒト初回投与（FIH）から世界各国の規制当局による承認、そして上市後まで、サターラは製薬企業が自信を持って科学に挑戦できるよう支援しています。
